Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 369Active not recruiting 83Unknown 65Terminated 63Recruiting 60Withdrawn 31Not yet recruiting 19Suspended 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2

Interventions

Paclitaxel 4Specimen Handling 3Magnetic Resonance Spectroscopy 3Trastuzumab 2Taxes 2Tamoxifen 2Interleukin-2 2Fluorouracil 2Cyclophosphamide 2Anastrozole 2trastuzumab biosimilar HLX02 1tivozanib 1taletrectinib 1palbociclib 1fluzoparib 1exemestane 1eribulin 1binimetinib 1atezolizumab 1aldesleukin 1Tomography, Optical Coherence 1Testosterone Propionate 1Testosterone 1Tablets 1Receptors, Chimeric Antigen 1Radiotherapy 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Suspended × Paclitaxel × Breast × Clear all
NCT05751668 2026-04-07

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
98 enrolled
Breast

Breast Neoplasms

NCT02037529 2024-08-20

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Academic and Community Cancer Research United

Phase 3 Suspended
201 enrolled 19 charts
Breast

Breast Neoplasms

NCT03002103 2023-04-26

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

SynCore Biotechnology Co., Ltd.

Phase 3 Suspended
420 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03777579 2019-08-08

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Suspended
375 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡